The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify

The Medicare GLP-1 discount program, which locks in a $50 price for GLP-1 drugs, is excluding millions of patients who have a qualifying diagnosis. According to Medical Daily, UA.NEWS and KFF Health News, nearly six million people are locked out of the program. The American Journal of Managed Care notes that as GLP-1 costs climb, Medicare Part D plans face a reckoning. The exclusion of these patients is a significant issue.

The American Journal of Managed Care, Medical Daily, UA.NEWS and KFF Health News all emphasize that the program's restrictions are preventing many sick patients from accessing necessary medications. Eli Lilly, a major pharmaceutical company, has launched an advertising campaign to promote GLP-1 access for Medicare enrollees, as noted by Yahoo and Fierce Pharma. This campaign focuses on aging and obesity, two conditions that are often treated with GLP-1 drugs. The situation is complicated by the fact that the discount program is not universally accessible.

While Eli Lilly's campaign aims to increase access, the restrictions imposed by the Medicare program mean that many patients will still be unable to benefit from the $50 price lock. The exact reasons for these exclusions are not specified in the coverage.